摘要
目的 :对胰岛素促泌剂瑞格列奈 (Repaglinide.诺和龙 )的疗效及安全性进行评价。方法 :将 6 4例 2型糖尿病患者分为瑞格列奈 (31例 )和糖适平 (33例 )组进行治疗和比较。结果 :治疗 4周后 ,两组患者 ,空腹血糖 (FBG)及餐后 2 h血糖 (2 h PG)均有显著下降 ,瑞格列奈治疗组 FBG及 2 h PG分别平均下降 2 .0 6 mmol/ L和 7.0 3mmol/ L (P<0 .0 5 ) ,糖适平治疗组 FBG及 2 h PG分别平均下降1.94 mmol/ L和 7.0 5 mmol/ L (P<0 .0 5 ) ,组间比较无显著差别 (P>0 .0 5 ) ;瑞格列奈治疗组低血糖发生率为 3.2 % ,而糖适平治疗组为 12 .1%。结论 :瑞格列奈对 2型糖尿病患者的代谢控制与糖适平效果相同 ,但低血糖发生率较糖适平治疗组为低 ,故是治疗 2型糖尿病的有效降糖药物 。
Objective:To evaluate the efficacy and safety of Repaglinde in type 2 diabeticpatients Methods:64 type 2 diabetic patients were assigned to Repaglinide or Glurenorm treatment group in 31:33 ratio Results:After 4 weeks of treatment,in the Repaglinide group the mean reduction of FBG and 2hPG was 2 06mmol/L and 7 03mmol/L respectively (P<0 05) in the Glurenorm group,the mean reduction of FBG and 2hPG was 1.94mmol/L and 7.05mmol/L respectively (P<0.05) The difference in reduction of FBG and 2hPG between the 2 groups was not statistically significant Furthemore,Frequency of hypoglycemia in the Repqglinide group was 3 2%,while that of Glurenorm group was 12 1% Conclusion:In comparision to Glurenorm,Repaglinide provides equal efficacy in metabolic control and afforded a significantly superior safey profile so that patients treated with it had higher treatment compliance
出处
《河北医学》
CAS
2002年第1期34-36,共3页
Hebei Medicine
